BRIEF published on 09/23/2024 at 08:20, 1 month 28 days ago Tissue Regenix Group Achieves First Pre-Tax Profit Market Expansion Pre-tax Profit Tissue Regenix Soft Tissue Repair Bone Repair
PRESS RELEASE published on 09/23/2024 at 08:15, 1 month 28 days ago Hardman & Co Research on Tissue Regenix (TRX): Maiden pre-tax profit Hardman & Co Research reports on Tissue Regenix (TRX) achieving maiden pre-tax profit. TRX focuses on soft tissue and bone repair technologies, showing strong growth and profitability Hardman & Co Research Pre-tax Profit Tissue Regenix Soft Tissue Repair Bone Repair
BRIEF published on 06/25/2024 at 10:48, 4 months 26 days ago Decline of UK Life Sciences Sector Raises Concerns Investment Tissue Regenix Institutional Support UK Life Sciences Healthcare Index
PRESS RELEASE published on 06/25/2024 at 10:43, 4 months 26 days ago Hardman & Co Insight: Survival of the UK life sciences sector Hardman & Co Research presents insights on the survival of the UK life sciences sector, highlighting challenges and opportunities for institutional investors. Discover more in the full report Investment Opportunities Hardman & Co Research Institutional Investors UK Life Sciences Sector Healthcare Stocks
BRIEF published on 04/10/2024 at 08:20, 7 months 11 days ago Hardman & Co Research Highlights Tissue Regenix's Impressive Growth Streak EBITDA Growth Tissue Regenix DCELL® BioRinse®
PRESS RELEASE published on 04/10/2024 at 08:15, 7 months 11 days ago Hardman & Co Research on Tissue Regenix (TRX): Six consecutive periods of >20% growth Hardman & Co Research highlights Tissue Regenix (TRX) with six consecutive periods of >20% growth, backed by strong commercial partners and expansion plans Hardman & Co Research Growth Investments Tissue Regenix EBITDA-positive
PRESS RELEASE published on 09/18/2023 at 11:40, 1 year 2 months ago Hardman & Co Research on Tissue Regenix (TRX): Continuing postive momentum 1H'23
PRESS RELEASE published on 04/05/2023 at 15:55, 1 year 7 months ago Hardman & Co Research on Tissue Regenix (TRX): Turning profitable and cash-generative
Published on 11/21/2024 at 10:03, 53 minutes ago Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 56 minutes ago BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 56 minutes ago ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 10 hours 21 minutes ago Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 31 minutes ago Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 10:30, 26 minutes ago MS Industrie AG publishes unaudited key figures for the first 3 quarters 2024
Published on 11/21/2024 at 10:04, 51 minutes ago Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 54 minutes ago Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 56 minutes ago Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 56 minutes ago Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV
Published on 11/21/2024 at 06:58, 3 hours 58 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 36 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 17 hours 11 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 17 hours 11 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 3 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
